Oracle Completes $20B ATM Offering, Ellison Plans 50M Share Sale
ORCL sits 31% above its 52-week low of $114.5 on elevated volume (2.4× avg).
Summary
Oracle's 10-Q confirms Q1 FY2027 results but reveals it fully utilized its $20B ATM program (141M shares for $19.9B), Ellison adopted a plan to sell up to 50M shares, and capex hit $28.5B with negative free cash flow.
Key Events · Earnings and Guidance · ORCL
-
$20B ATM Program Fully Utilized
Oracle issued 141 million shares under its at-the-market program for $19.9 billion in net proceeds during Q1 FY2027, fully exhausting the $20 billion authorization.
-
Ellison Adopts 50M Share Sale Plan
Executive Chairman and CTO Lawrence J. Ellison adopted a Rule 10b5-1 trading plan on June 22, 2026 to sell up to 50 million shares, with the plan scheduled to terminate October 24, 2026.
-
Restructuring Plan Expanded by $700M
Management supplemented the 2026 Restructuring Plan by approximately $700 million after August 31, 2026, bringing total estimated restructuring costs to roughly $2.8 billion.
-
Capex Surges to $28.5B, FCF Negative
Capital expenditures reached $28.5 billion in Q1 FY2027, up from $8.5 billion a year earlier, driving free cash flow to negative $5.4 billion.
Analysis · ORCL · Technology
Oracle's Q1 FY2027 10-Q confirms the blowout quarter already reported in the 8-K, but the real news is in the details: the company fully utilized its $20 billion at-the-market offering program, issuing 141 million shares for $19.9 billion in net proceeds. That's a massive capital raise to fund its AI data center buildout, and it comes with real dilution for existing shareholders. Adding to the overhang, Executive Chairman and CTO Lawrence Ellison adopted a Rule 10b5-1 plan to sell up to 50 million shares between June and October 2026. The company also disclosed it supplemented its restructuring plan by another $700 million, bringing total expected costs to roughly $2.8 billion, and that capital expenditures hit $28.5 billion in the quarter — more than triple the prior year. Free cash flow was negative $5.4 billion. The market already knew about the revenue growth and RPO, but the scale of the equity issuance and the insider selling plan are new material facts that change the risk calculus for shareholders.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORCL was trading at $150.15 on NYSE in the Technology sector, with a market capitalization of approximately $432.9B. The 52-week trading range was $114.50 to $331.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.